tiprankstipranks
Blurbs

Analysts Are Bullish on These Healthcare Stocks: IQVIA Holdings (IQV), CVS Health (CVS)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on IQVIA Holdings (IQVResearch Report), CVS Health (CVSResearch Report) and Lantheus (LNTHResearch Report) with bullish sentiments.

IQVIA Holdings (IQV)

In a report released yesterday, Jailendra Singh from Truist Financial maintained a Buy rating on IQVIA Holdings, with a price target of $292.00. The company’s shares closed last Wednesday at $227.88.

According to TipRanks.com, Singh is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -13.9% and a 33.9% success rate. Singh covers the Healthcare sector, focusing on stocks such as Privia Health Group, Hims & Hers Health, and GoodRx Holdings.

Currently, the analyst consensus on IQVIA Holdings is a Strong Buy with an average price target of $278.40, representing a 21.8% upside. In a report issued on May 2, Jefferies also maintained a Buy rating on the stock with a $266.00 price target.

See the top stocks recommended by analysts >>

CVS Health (CVS)

In a report released yesterday, David S Macdonald from Truist Financial maintained a Buy rating on CVS Health, with a price target of $66.00. The company’s shares closed last Wednesday at $54.91, close to its 52-week low of $53.70.

According to TipRanks.com, Macdonald is a 5-star analyst with an average return of 12.6% and a 64.5% success rate. Macdonald covers the Healthcare sector, focusing on stocks such as Walgreens Boots Alliance, Pediatrix Medical Group, and Option Care Health.

Currently, the analyst consensus on CVS Health is a Moderate Buy with an average price target of $70.41, which is a 26.2% upside from current levels. In a report issued on May 1, Mizuho Securities also maintained a Buy rating on the stock with a $72.00 price target.

Lantheus (LNTH)

In a report released yesterday, Richard Newitter from Truist Financial maintained a Buy rating on Lantheus, with a price target of $96.00. The company’s shares closed last Wednesday at $74.51.

According to TipRanks.com, Newitter is a 5-star analyst with an average return of 17.9% and a 60.3% success rate. Newitter covers the Healthcare sector, focusing on stocks such as Treace Medical Concepts, Inspire Medical Systems, and Zimmer Biomet Holdings.

Currently, the analyst consensus on Lantheus is a Strong Buy with an average price target of $101.71, representing a 34.1% upside. In a report issued on May 3, JMP Securities also reiterated a Buy rating on the stock with a $100.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on IQV:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles